AI Article Synopsis
- Fusion is an emerging target in precision oncology, found in various solid tumors, but research is often focused on more common types, creating challenges in treatment planning for rare cases.
- The case presented involves a rare high-grade serous tubo-ovarian carcinoma with a unique fusion, which responded briefly to the drug futibatinib.
- The study explores the possible mechanisms behind this fusion and highlights difficulties in predicting how effective targeted therapies will be for different tumor types that share similar structural variants.
Article Abstract
fusion is one of the classes of emerging therapeutic targets of precision oncology and is observed in many solid tumor types. Our understanding of oncogenic mechanisms and therapy effects of molecular targets tends to reflect those occurring in overrepresented tumor types, posing a challenge in therapy planning of the same targets occurring in unusual tumor types. We present a case of a primary high-grade serous tubo-ovarian carcinoma with a novel fusion, an exceedingly rare combination of tumor type and fusion class, with an unusually short-lived response to futibatinib. We review the potential pathogenic mechanism of this fusion and address challenges in predicting targeted therapy efficacy using various assay types and trial designs in heterogeneous tumor types sharing a structural variant.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695219 | PMC |
| http://dx.doi.org/10.3389/fonc.2024.1514471 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!